The cancer vaccine is likely quite far away. I think there are a couple other agents more likely to beneficial in the near term, namely:
*Stemmness inhibitor, napabucasin in combination with FOLFIRI currently in multiple stage III trials, with the first completing in June 2020,
https://clinicaltrials.gov/ct2/show/NCT02753127*A small efficacy signal was shown for a CTLA4 and PDL1 immunotherapy combination (for MSS), which will likely launch a phase three trial.
https://www.onclive.com/web-exclusives/ ... actory-crc*Bi specific CEA TMB (RO6958688) in combination with PD-L1 has shown good efficacy in current trials with manegable toxicity. I think Phase III testing could begin within a year
https://m.soundcloud.com/bmjpodcasts/ne ... tal-cancerI. was personally hoping for the development of new immunotherapy biomarkers (namely PBRM1), but the latest data suggests this won’t pan out.
Please let me know if I got any of these wrong, or add your own favorites.